Month: July 2020

BRAINTREE, Mass., July 22, 2020 (GLOBE NEWSWIRE) — Altra Industrial Motion Corp. (Nasdaq: AIMC), a leading global manufacturer and supplier of motion control, power transmission and automation products, today announced that its Board of Directors has approved the payment of a quarterly cash dividend of $0.04 per share for the third quarter of 2020. The third quarter 2020 dividend is the thirty-fourth consecutive dividend in the Company’s history. The dividend will be paid on October 2, 2020 to shareholders of record as of the close of business on September 18, 2020. Future declarations of quarterly cash dividends are subject to approval by the Board of Directors and to the Board’s continuing determination that the declaration of dividends is in the best interests of Altra’s shareholders and is in compliance with all...

NEWMARKET, Ontario, July 22, 2020 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (the “Company”), announced today that it will release its second quarter 2020 results after market close on Monday August 10, 2020. The release will be followed by a conference call to discuss its second quarter 2020 financial results on Tuesday August 11, 2020 at 9:00 am ET.SECOND QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL DETAILS:Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. Contact: Chris Bitsakakis, President or Gren Schoch, CEO at 905-751-1188.AirBoss of America Corp. is a group of complementary businesses supplying custom compounded rubber, survivability solutions and anti-vibration components to a diverse group of customers globally. AirBoss Rubber Solutions is a top-tier North...

Utrecht, 22 July 2020   highlightso revenue EUR 1,287 million; organic -11.1%o operating profit (EBITA) EUR 121.7 million; EBITA-margin 9.5%o net profit before amortisation EUR 85.6 million; per share EUR 0.77o solid cash flow from operations EUR 68 milliono orderbook end of June higher than last yearo continued investments and innovation initiatives; CAPEX EUR 53.8 milliono acceleration strategy: one-off full year strategic restructuring cost of approx. EUR 40 million with an annual benefit of approx. EUR 45 million  CEO statement“We are fortunate that we only faced a limited amount of COVID-19 infections. Our business was impacted with an organic revenue decline of 11% during the first half of the year. We focused on cash management and cost optimisations. From the last weeks of May we see an increase in our order intake and sales....

  Phase 2 study VLA15-201 met its endpointsCompared to Phase 1, the higher doses used in this trial elicited higher antibody responses across all serotypesEncouraging immunogenicity profile confirmed, including older adults (50-65 years)VLA15 generally safe across all dose and age groups testedNo related Serious Adverse Events (SAEs) associated with VLA15Saint-Herblain (France), July 22, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine candidate VLA15.VLA15 was immunogenic across all dose groups tested. Compared to Phase 1, the higher doses used in this trial elicited higher antibody responses across all serotypes. Seroconversion rates (SCR) in the highest dose ranged...

Critère principal de l’étude de Phase 2 VLA15-201 atteintComparé à la Phase 1, les plus fortes doses du vaccin utilisées dans cet essai ont généré des réponses anticorps plus élevées dans tous les sérotypesProfil d’immunogénicité encourageant y compris chez les adultes les plus âgés (50 à 65 ans) VLA15 a été généralement bien toléré pour toutes les doses et dans tous les groupes testésAucun effet indésirable sévère constaté avec VLA15Saint-Herblain (France), 22 juillet 2020 – Valneva SE (“Valneva”), société spécialisée dans les vaccins a annoncé aujourd’hui des résultats initiaux positifs pour la première des deux études de Phase 2 (VLA15-201) de son candidat vaccin contre la maladie de Lyme, VLA15.VLA15 a démontré être immunogène dans toutes les doses testées. Comparé à la Phase 1, des doses plus fortes du vaccin utilisées dans cet essai...

Wereldhave updates on a revised credit rating by Moody’s Investor Service, (“Moody’s”). We want to provide more clarity on the recent downgrade of Wereldhave N.V.’s corporate family rating and the rating on the senior unsecured bonds to B1 from Ba2 and has placed the ratings on review for downgrade. The outlook has changed to ratings under review from negative.Wereldhave understands that the downgrade by Moody’s is related to a short dated debt maturity profile and refinancing needs. Wereldhave recognizes that the Covid-19 pandemic has had an adverse effect on capital markets due to increased uncertainties. This results in longer periods for negotiating new financing deals. Wereldhave is in active and constructive dialogues with various lenders to extend and/or refinance debt maturities for 2021 and beyond. Added with Wereldhave’s liquidity...

Article L.233-8 II du Code de commerce et article 223-16 du Règlement général de l’Autorité des marchés financiersDénomination sociale de l’émetteur :         Derichebourg119, Avenue du Général Michel Bizot75012 PARIS* Nombre de droits de votes exerçables = nombre de droits de vote théoriques (ou nombre total de droits de vote attachés aux actions) – actions privées du droit de vote.Code ISIN : FR 0000053381 – DBGPièce jointeDroits de vote au 31 mai 2020

NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended June 30, 2020 after the close of the market on Wednesday, August 5, 2020.The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.Interested participants in the United States may access the conference call by dialing 1.877.883.0383 and using the passcode 4278956.  International participants may access the call by dialing 1.412.902.6506 and using the same passcode.An audio replay of the call will be available through Tuesday, August 11, 2020 and may be...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favourable benefit-risk profilePDS is a permanent refillable eye implant that continuously delivers a customised formulation of ranibizumab over a period of months, potentially reducing the treatment burden associated with frequent eye injectionsData from the study will be discussed at the upcoming 38th Annual Meeting of the American Society of Retina SpecialistsBasel, 22 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading...